September 1, 2018
A new permanent research scientist, Dr Nina Fenouille, is now joining the Puissant lab to investigate mechanisms of chemoresistance in AML using innovative screening technologies.
May 16, 2018
Raphael Itzykson has recently discovered that the presence of multiple clones harboring muta-tions in the RTK/RAS pathway imparts an adverse prognosis in Core Binding Factor AML, while the presence of a single RTK/RAS clone has no impact on prognosis.
These findings have been published in The Blood Journal. Thanks to the support of The Fondation ARC, further work is ongoing to elucidate the role of the clonal interference of RTK/RAS pathway signaling in AML.
January 25, 2018
Among the best young researchers in life sciences, Alex Puissant has been selected by The Schlumberger Foundation for Education and Research (FSER) to support the creation of our lab, giving us the best chance to develop our work.
October 10, 2017
Alex Puissant is laureate of the 2017 ERC Starting Grants that fund the top talented young researchers across Europe. This funding will enable us to set up our lab and pursue ground-breaking ideas from basic science to leukemia treatment.